- Home
- TROO vs QNCX Comparison
TROO vs QNCX Comparison
Compare TROO & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- QNCX
- Stock Information
- Founded
- TROO 2005
- QNCX 2012
- Country
- TROO Hong Kong
- QNCX United States
- Employees
- TROO N/A
- QNCX N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TROO Technology
- QNCX Health Care
- Exchange
- TROO Nasdaq
- QNCX Nasdaq
- Market Cap
- TROO 103.8M
- QNCX 85.9M
- IPO Year
- TROO N/A
- QNCX 2019
- Fundamental
- Price
- TROO $1.34
- QNCX $1.75
- Analyst Decision
- TROO
- QNCX Strong Buy
- Analyst Count
- TROO 0
- QNCX 6
- Target Price
- TROO N/A
- QNCX $8.00
- AVG Volume (30 Days)
- TROO 179.7K
- QNCX 363.9K
- Earning Date
- TROO 11-14-2025
- QNCX 11-12-2025
- Dividend Yield
- TROO N/A
- QNCX N/A
- EPS Growth
- TROO N/A
- QNCX N/A
- EPS
- TROO N/A
- QNCX N/A
- Revenue
- TROO $10,073,000.00
- QNCX N/A
- Revenue This Year
- TROO N/A
- QNCX N/A
- Revenue Next Year
- TROO N/A
- QNCX N/A
- P/E Ratio
- TROO N/A
- QNCX N/A
- Revenue Growth
- TROO 182.24
- QNCX N/A
- 52 Week Low
- TROO $0.49
- QNCX $0.69
- 52 Week High
- TROO $3.05
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- TROO 59.53
- QNCX 60.70
- Support Level
- TROO $1.16
- QNCX $1.59
- Resistance Level
- TROO $1.54
- QNCX $1.68
- Average True Range (ATR)
- TROO 0.17
- QNCX 0.10
- MACD
- TROO -0.01
- QNCX 0.03
- Stochastic Oscillator
- TROO 45.20
- QNCX 45.83
About TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.